A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

Studied

Phase 2 randomized trial comparing daily semaglutide with placebo for fatty liver inflammation and scarring.

Who / model

320 patients with biopsy-confirmed liver inflammation and fibrosis, treated for 72 weeks; main liver analyses included 230 with more advanced fibrosis.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

At the highest studied dose, inflammation resolved without worse scarring in 59% versus 17%. Scarring improved in 43% versus 33%, a difference that was not statistically clear. Weight fell 13% versus 1%. Digestive adverse events were more common. Tumors were reported in 15% across semaglutide groups versus 8% with placebo, including malignant tumors in 1% versus none.

Limits

Study limitations were not stated in the abstract. Methodological quality has not been appraised.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary